Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 204 of the 206 references it cites were found in a registry or an index; 68 of the 244 sources its claims cite were checked for support.
Abstract
Objective The aim was to develop clinical practice guidelines on hypertriglyceridemia. Participants The Task Force included a chair selected by The Endocrine Society Clinical Guidelines Subcommittee (CGS), five additional experts in the field, and a methodologist. The authors received no corporate funding or remuneration. Consensus process Consensus was guided by systematic reviews of evidence, e-mail discussion, conference calls, and one in-person meeting. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments. Conclusions The Task Force recommends that the diagnosis of hypertriglyceridemia be based on fasting levels, that mild and moderate hypertriglyceridemia (triglycerides of 150-999 mg/dl) be diagnosed to aid in the evaluation of cardiovascular risk, and that severe and very severe hypertriglyceridemia (triglycerides of > 1000 mg/dl) be considered a risk for pancreatitis. The Task Force also recommends that patients with hypertriglyceridemia be evaluated for secondary causes of hyperlipidemia and that subjects with primary hypertriglyceridemia be evaluated for family history of dyslipidemia and cardiovascular disease. The Task Force recommends that the treatment goal in patients with moderate hypertriglyceridemia be a non-high-density lipoprotein chole…
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline recommends evaluating and treating hypertriglyceridemia with fasting triglyceride measurement, secondary-cause workup, lifestyle therapy for mild-to-moderate elevations, and combined diet plus drug therapy for severe/very severe hypertriglyceridemia to prevent pancreatitis. It also concludes that triglycerides are associated with cardiovascular risk but whether they are causal remains uncertain.
Key findings
- The guideline recommends screening adults with a fasting lipid panel at least every 5 yr (1/QQEE), basing hypertriglyceridemia diagnosis on fasting rather than nonfasting triglycerides (1/QQQE), and against routine lipoprotein particle heterogeneity measurement (1/QQEE).
- It defines moderate hypertriglyceridemia as 200–999 mg/dl, severe as 1000–1999 mg/dl, and very severe as ≥2000 mg/dl; for severe/very severe hypertriglyceridemia (>1000 mg/dl), it recommends combining dietary fat and simple carbohydrate reduction with drug treatment to reduce pancreatitis risk (1/QQQQ), with fibrate as first-line for triglyceride-induced pancreatitis (1/QQQE).
- Lifestyle therapy is recommended initially for mild-to-moderate hypertriglyceridemia (1/QQEE); for moderate hypertriglyceridemia, the treatment goal is a non-HDL cholesterol level in agreement with NCEP ATP guidelines (1/QQEE); statins should not be used as monotherapy for severe or very severe hypertriglyceridemia but may be useful for moderate hypertriglyceridemia to modify cardiovascular risk (1/QQEE).
- In NHANES 1999–2004, 33% of nearly 6000 participants had serum triglycerides ≥150 mg/dl (42% among those aged ≥60 yr); about 14% had 150–200 mg/dl, 16% had 200–500 mg/dl, and about 2% had >500 mg/dl. Meta-analytic estimates included an adjusted odds ratio of 1.72 (95% CI, 1.56–1.90) for coronary heart disease comparing top vs bottom triglyceride tertiles, and an ERFC hazard ratio of 1.37 (95% CI, 1.31–1.42) after adjustment for nonlipid factors, reduced to 0.99 (95% CI, 0.94–1.05) after adjustment for HDL and non-HDL cholesterol.
Methods
- The Task Force followed the GRADE approach: strong recommendations use “we recommend” and number 1; weak recommendations use “we suggest” and number 2; evidence quality is denoted QEEE (very low), QQEE (low), QQQE (moderate), and QQQQ (high).
- The guideline was developed by a chair selected by The Endocrine Society Clinical Guidelines Subcommittee, five additional experts, and a methodologist; evidence included observational/epidemiological studies and a systematic review/meta-analysis commissioned by The Endocrine Society.
- Funding was derived solely from The Endocrine Society, and the Task Force received no corporate funding or remuneration.
Limitations
- The Task Force states that it acknowledges the observational nature of the available evidence and dependence on epidemiological studies, and that it made several strong recommendations based on assumptions about patients’ values and preferences.
- The paper states that whether serum triglycerides are causally related to atherosclerosis remains to be elucidated, that elevated triglycerides may sometimes be a marker rather than a causal factor, and that there is a lack of clear human data showing triglyceride reductions reduce cardiovascular disease.
- Stated limitations of specific evidence include lack of standardization and reference levels for nonfasting triglycerides, and for the Copenhagen City Heart Study analysis, a small number of subjects with high triglycerides, no adjustment for HDL cholesterol, and lack of fasting triglyceride levels for comparison.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
53 Valid · 24 Not valid · 106 Not checked · 100 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Epidemiological studies vary as to the independent association between large or small LDL and atherosclerotic cardiovascular disease (30).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Partly supportedcites [30] Austin, 1990, Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk., Circulation sourceExperimental — accuracy not yet measured
The introduction (p. 495) reports that the small, dense LDL phenotype was associated with increased myocardial infarction risk, consistent with two previous studies. But the paper does not say that epidemiological studies vary in their findings about an independent association of large or small LDL with cardiovascular disease. Its multivariate analysis examines associations with LDL phenotype, not independent associations with disease. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Prospective multivariate studies demonstrate that large LDL predicts atherosclerosis and coronary heart disease (35,38,39).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Not checked — no full text of the sourcecites [35] Sacks, 2003, Low density lipoprotein and cardiovascular disease: a reappraisal. (Clinical Review 163)., J Clin Endocrinol Metab source
- Partly supportedcites [38] Mora, 2009, Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women., Circulation sourceExperimental — accuracy not yet measured
The Results (Association of NMR Lipoproteins, Lipids, and Apolipoproteins with CVD; page unavailable) report that large LDL particles were significantly associated with incident cardiovascular disease in women when all nine particle subclasses were included in the model. They were not associated with cardiovascular disease in the separate adjusted model. The paper does not establish that large LDL specifically predicts atherosclerosis or coronary heart disease. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [39] Campos, 2001, Low density lipoprotein size, pravastatin treatment, and coronary events., JAMA source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Several reports also show that measurement of apoB is superior to measurement of LDL or even non-HDL cholesterol as an indicator of global CVD risk (40,41).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Not checked — no full text of the sourcecites [40] de Graaf, 2008, A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias., Nat Clin Pract Endocrinol Metab source
- Supportedcites [41] Holewijn, 2010, Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk., J Intern Med source
The Discussion reports that, in this population-based sample, apoB identified people with a compromised cardiovascular risk profile more effectively than non-HDL cholesterol, while LDL cholesterol was least effective. It also reports significantly greater discrimination of prevalent CVD for apoB than for non-HDL cholesterol. The finding is based on this cohort; the authors note that a cited meta-analysis found no difference between apoB and non-HDL cholesterol. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several prospective studies suggest that circulating levels of small, dense LDL particles are better predictors of coronary atherosclerosis, carotid atherosclerosis, and response to therapy than are levels of large, buoyant LDL particles (28,(31)(32)(33).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Partly supportedcites [28] Zambon, 1999, Evidence for a new pathophysiological mechanism for coronary artery regression: hepatic lipase-mediated changes in LDL density., Circulation sourceExperimental — accuracy not yet measured
The Abstract reports prospective associations between LDL size or density and coronary artery disease, and says patients with small, dense LDL responded better to therapy than those with large, buoyant LDL. The Results link changes in LDL buoyancy to changes in coronary stenosis. The cited paper does not address carotid atherosclerosis, so it does not support that part of the claim. Page numbers are unavailable in our copy. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [31] St-Pierre, 2005, Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study., Arterioscler Thromb Vasc Biol source
- Not checked — no full text of the sourcecites [32] Mora, 2007, LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)., Atherosclerosis source
- Partly supportedcites [33] Musunuru, 2009, Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk., Arterioscler Thromb Vasc Biol sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that small and medium LDL particle levels were associated with cardiovascular disease, whereas large LDL particle levels were not significantly related; it also says this pattern agrees with prospective cohorts including a study of carotid atherosclerosis. It does not establish that small, dense LDL levels predict response to therapy better than large LDL levels. Instead, the Discussion proposes evaluating lipoprotein measures in treatment studies as future work. (LLM, conf=0.84)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Prospective studies have indicated that, compared with fasting levels, nonfasting serum triglyceride levels may be a better or similar predictor of CVD events in the general population (15-18).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.2. Evidence
What the sources say
- Not checked — no full text of the sourcecites [15] Nordestgaard, 2007, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women., JAMA source
- Not checked — no full text of the sourcecites [16] Bansal, 2007, Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women., JAMA source
- Supportedcites [17] Mora, 2008, Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events., Circulation source
The paper’s introductory passage says three studies suggested that nonfasting triglycerides may predict CVD events better than or similarly to fasting levels. Its Results also report a stronger association for nonfasting triglycerides in its prospective cohort of initially healthy women. No page number is available in our copy. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [18] Stalenhoef, 2008, Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small, dense LDL., Curr Opin Lipidol source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
149 more claims · 26 with their cited sources checked
Create a free account to see all 283 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 53
- It may state two separate claims as one. 94
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HTG may result from impaired clearance of TRLs, most often due to pathogenic variants in the lipolytic pathway, ranging from monogenic defects in LPL gene or its cofactors (APOC2, APOA5, LMF1, and GPIHBP1) to polygenic susceptibility, and may be exacerbated by secondary factors such as diabetes, obesity, alcohol use, and certain medications [5, 6].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current management strategies for HTG and mixed dyslipidemia provide limited and inconsistent benefits in TG lowering and cardiovascular outcomes, underscoring the need for more effective and durable approaches targeting TRL and apoB-containing lipoproteins (Filtz et al., 2024; Berglund et al., 2012; Chapman et al., 2011).”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Berglund et al., 2012
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A delay in diagnosis may place patients at an increased risk for acute pancreatitis.11”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [11]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The APPROACH trial showed that volanesorsenmediated lowering of plasma apolipoprotein C-III levels in patients with familial chylomicronemia syndrome effectively lowered plasma triglycerides below the threshold of 750 to 880 mg per deciliter”
From Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome (2019) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Acute pancreatitis can lead to chronic pancreatitis, 10,11 signs of exocrine or endocrine pancreatic insufficiency, including pancreatic (type 3c) diabetes, 12 and can be fatal.”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [11]
Experimental — accuracy not yet measured
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.1. Evidence
“Of subjects with hypertriglyceridemia, about 14% had mild hypertriglyceridemia (150 -200 mg/dl), whereas 16% had triglyceride levels of 200 -500 mg/dl, and about 2% had levels above 500 mg/dl.”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.1. Evidence
“In the National Health and Nutrition Examination Survey (NHANES), 1999 -2004, 33% of the nearly 6000 participants (37% men, 30% women) had serum triglycerides of at least 150 mg/dl (Ն1.7 mmol/liter) (5).”
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860 · cited 7×
“Cosponsoring Associations: American Heart Association, European Society of Endocrinology.”
InfluentialDetection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation group (1).”
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Research works printed but not linked: 2
- Assmann, 1993, Results and conclusions of the prospective cardiovascular Munster (PROCAM) study, 19
- Brunzell, 2001, Familial lipoprotein lipase deficiency, ApoC-II deficiency, and hepatic lipase deficiency, 2789
Cited by
Items 201–300 of 886
Corona, G., Cipriani, S., Rastrelli, G., Sforza, A., Mannucci, E., & Maggi, M. (2016) · Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.07.004 · Cited by 33
Consensus statement on the management of dyslipidaemias in adults
Béliard, S., Bonnet, F., Bouhanick, B., Bruckert, É., Cariou, B., Charrière, S., Durlach, V., Moulin, P., Valéro, R., & Vergès, B. L. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.07.033 · Cited by 23
Diagnosis and Management of Acute Pancreatitis
Mittal, N., Oza, V. M., Muniraj, T., & Kothari, T. H. (2025) · Diagnostics · doi:10.3390/diagnostics15030258 · Cited by 43
“The Endocrine Society classifies hypertriglyceridemia into mild (150–500 mg/dL), moderate (500–1000 mg/dL), or severe (>1000 mg/dL) forms [22].”
Hypertriglyceridemic pancreatitis associated with confounding laboratory abnormalities
Melnick, S., Nazir, S., Gish, D., & Aryal, M. R. (2016) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.3402/jchimp.v6.31808 · Cited by 28
“Discussion HTG is defined as fasting TG levels greater than 150 mg/dl and levels exceeding 1,000 mg/dl is defined as severe HTG (1).”
BackgroundHypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care
Hartz, J. C., de Ferranti, S. D., & Gidding, S. S. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00079 · Cited by 32
Lamíquiz-Moneo, I., Mateo‐Gállego, R., Pardo, J. F., López-Ariño, C., Marco-Benedí, V., Bea, A. M., Ferraro, L., Jarauta, E., Cenarro, A., & Civeira, F. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.10.897 · Cited by 50
Nakhoda, S., Zimrin, A. B., Baer, M. R., & Law, J. Y. (2016) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2016.10.005 · Cited by 28
Chylomicronemia Syndrome: Very Severe Hypertriglyceridemia and Acute Pancreatitis
Wierzbicki, A. S. (2018) · Endocrine and Metabolic Medical Emergencies · doi:10.1002/9781119374800.ch44 · Cited by 28
Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review
Zimodro, J. M., Rizzo, M., & Gouni‐Berthold, I. (2025) · Pharmaceuticals · doi:10.3390/ph18020147 · Cited by 32
“Classification of HTG is inconsistent [23–26], as presented in Table 1.”
Feingold, K. R. (2015) · Europe PMC (PubMed Central) · Cited by 36
de Vries, M. A., Klop, B., & Cabezas, M. C. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.03.024 · Cited by 29
“It should be noted that differentiation between FCH and FH can be difficult even when using fasting lipid profiles, because FCH can be present if triglycerides are normal or almost normal, and FH can be accompanied by elevated triglycerides due to the genetic heterogeneity of the primary lipid disorders [30].”
BackgroundAraz, F., Bakıner, O., Bağır, G. Ş., Soydaş, B., Özer, B., & Kozanoğlu, İ. (2020) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002025 · Cited by 30
Tai, W.-P., Lin, X.-C., Liu, H., Wang, C., Wu, J., Zhang, N., & Chen, W. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/6263095 · Cited by 25
“2mmol/L (200mg/dL) [19, 20].”
Zambon, A., Zhao, X.-Q., Brown, B. G., & Brunzell, J. D. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.01.426 · Cited by 26
“Additional patients at risk for CVD with small, dense LDL particles might benefit from niacin combination therapy.(30) It is important to confirm these findings in large clinical trials such as AIM-HIGH.”
BackgroundSelf-citationPedersen, S. B., Varbo, A., Langsted, A., & Nordestgaard, B. G. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12713 · Cited by 29
“Risk factors for chylomicronemia Risk factors for chylomicronemia were chosen based on knowledge on secondary causes of hypertriglyceridemia[4-7].”
BackgroundMethodInfluentialLi, Q., Hou, C., Peng, Y., Zhu, X., Shi, C., Zhang, K., Tu, M., Guo, F., Huang, D., & Miao, Y. (2019) · BioMed Research International · doi:10.1155/2019/2620750 · Cited by 28
“According to the Guidelines of the American College of Gastroenterology and the Endocrine Society, high TG levels (≥1000mg/dL) should be considered as a risk factor for developing acute pancreatitis [10, 11].”
Berberich, A. J., Ouédraogo, A. M., Shariff, S. Z., Hegele, R. A., & Clemens, K. K. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01517-6 · Cited by 31
“6 mmol/L) [1], the approximations of 10 and 20 mmol/L, respectively, are more practical for a Canadian population.”
BackgroundWhat Causes Premature Coronary Artery Disease?
Le, A., Peng, H., Golinsky, D., Scipio, M. D., Lali, R., & Paré, G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01200-y · Cited by 38
“Familial hyperchylomicronemia syndrome (FCS) is most commonly attributed to autosomal recessive mutation in the LPL gene coding for the lipoprotein lipase (LPL) enzyme [57–59].”
Bai, J., Zheng, S., Jiang, D., Han, T., Li, Y., Zhang, Y., Liu, W., Cao, Y., & Hu, Y. (2015) · PubMed · Cited by 31
Tan, M., Mo, C.-Y., Li, F., & Zhao, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1215521 · Cited by 26
Wang, J., Xia, Y., Cao, Y., Cai, X., Jiang, S., Liao, Y., Shi, M., Luo, H., & Wang, D. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01968-z · Cited by 31
Cefalu, A. B., Spina, R., Noto, D., Ingrassia, V., Valenti, V., Giammanco, A., Fayer, F., Misiano, G., Cocorullo, G., Scrimali, C., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.01.003 · Cited by 28
Li, X., Pu, N., Chen, W., Shi, X., Zhang, G., Ke, L., Ye, B., Tong, Z., Wang, Y., Liu, C., et al. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01249-z · Cited by 27
Pothoulakis, I., Paragomi, P., Tuft, M., Lahooti, A., Archibugi, L., Capurso, G., & Papachristou, G. I. (2021) · Digestion · doi:10.1159/000512682 · Cited by 27
Duan, J., Huang, Z., Nice, E. C., Xie, N., Chen, M., & Huang, C. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.08.007 · Cited by 26
“However, triglyceride accumulation in the liver and hypertriglyceridemia induced by rapamycin may cause non-liver-related death [149].”
BackgroundYang, X., Shi, N., Yao, L., He, W., Zhu, P., Li, S., Li, L., Li, Y., Liu, S., Deng, L., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.998499 · Cited by 29
“DM, dyslipidaemia and their treatment are highly linked (18, 19).”
BackgroundRhodes, K. S., Weintraub, M., Marchlewicz, E. H., Rubenfire, M., & Brook, R. D. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.03.012 · Cited by 25
“It is suspected that there was a large degree of under-reported alcohol intake especially secondary to binge drinking,(23) which may limit treatment effects.(3) It is important to reinforce the importance of alcohol limitation in individuals with hypertriglyceridemia.”
BackgroundYamada, H., Kikuchi, S., Hakozaki, M., Motodate, K., Nagahora, N., & Hirose, M. (2016) · Journal of Lipids · doi:10.1155/2016/7498508 · Cited by 26
Severe Hypertriglyceridemia in Pregnancy: A Case Report and Review of the Literature
Kleess, L., & Janicic, N. (2018) · AACE Clinical Case Reports · doi:10.4158/accr-2018-0168 · Cited by 31
“Diet, genetic defects, insulin resistance, and medications can all play a role (1-2).”
BackgroundDing, L., Guan, L., Li, X., Xu, X., Zou, Y., He, C., Hu, Y., Wan, J., Huang, X., Lei, Y., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.11.006 · Cited by 25
Origin and therapy for hypertriglyceridaemia in type 2 diabetes
Pang, J., Chan, D. C., & Watts, G. F. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i2.165 · Cited by 26
Inhibition of ApoCIII: the next PCSK9?
Moens, S. J. B., van Capelleveen, J. C., & Stroes, E. S. G. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000130 · Cited by 25
Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs
KONES, R. J., & Rumana, U. (2015) · Drugs · doi:10.1007/s40265-015-0429-3 · Cited by 27
Yang, Y., Kim, H., Kim, S., & Moon, M. K. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.12 · Cited by 30
Ospina, N. S., Rodríguez‐Gutiérrez, R., Brito, J. P., Young, W. F., & Montori, V. M. (2015) · BMC Medicine · doi:10.1186/s12916-015-0435-z · Cited by 28
Macho‐González, A., Garcimartín, A., López‐Oliva, M. E., Celada, P., Bastida, S., Benedí, J., & Sánchez-Muniz, F. J. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.103600 · Cited by 26
Gut Mycobiome Dysbiosis is Linked to Hypertriglyceridemia Among Home Dwelling Elderly DanesPreprint
Ahmad, H. F., Castro-Mejía, J. L., Krych, Ł., Khakimov, B., Kot, W., Bechshøft, R. L., Reitelseder, S., Højfeldt, G. W., Engelsen, S. B., Holm, L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.16.044693 · Cited by 26
Stefanutti, C., & Julius, U. (2015) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2015.02.017 · Cited by 24
“The Endocrine Society Clinical Practice Guideline recommends lifestyle changes and exercise for mild-moderate HTG and additionally drug therapy for severe to very severe HTG [37].”
BackgroundChaudhary, A., Iqbal, U., Anwar, H., Siddiqui, H. U., & Alvi, M. (2017) · Gastroenterology Research · doi:10.14740/gr762e · Cited by 24
Xie, Y., Xu, Y.-H., Chen, Z., Lu, W.-F., Li, N., Wang, Q., Shao, L., Li, Y., Yang, G., & Bian, X. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.09.073 · Cited by 23
Tan, H. L. E., McDonald, G., Payne, A. R., Yu, W., Ismadi, Z., Tran, H. A., Gani, J., & Wynne, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123954 · Cited by 25
“This cut-off is consistent with the Endocrine Society guidelines for severe hypertriglyceridemia and is considered to be a level that plausibly has a causative role in AP [1,20].”
MethodInfluentialDai, W., Lund, H., Chen, Y., Zhang, J., Osinski, K. I., Zellner-Jones, S., Kreuziger, L. B., López, J. A., Benjamin, I. J., Silverstein, R. L., et al. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.08.002 · Cited by 23
Alsayed, N., Almahmeed, W. A., Alnouri, F., Al-Waili, K., Sabbour, H. M., Sulaiman, K., Zubaid, M., Ray, K. K., & Al‐Rasadi, K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.022 · Cited by 25
Prescription omega-3 fatty acid products: Considerations for patients with diabetes mellitus
Avallone, L., Shaikh, A., Hassan, A., & Tajuddin, N. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s97036 · Cited by 22
“The 2012 Endocrine Society clinical practice guideline on evaluation and treatment of hypertriglyceridemia, though not specific to patients with T2DM, recommends that drug therapies such as fibrates, niacin, or OM3FAs (alone or in combina tion with statins) be considered for treatment of moderate to severe TG levels.…”
BackgroundInfluentialThe Epigenetic Regulation of RNA N6-Methyladenosine Methylation in Glycolipid Metabolism
Yang, H., Li, Y., Huang, L., Fang, M., & Xu, S. (2023) · Biomolecules · doi:10.3390/biom13020273 · Cited by 25
Xie, Z., He, Z., Ye, Y., & Mao, Y. (2022) · Nutrition · doi:10.1016/j.nut.2022.111764 · Cited by 29
The nature and characteristics of hypertriglyceridemia in a large cohort with type 2 diabetes
Echegoyen, F. F. B., Szeto, A., Mendez, A. J., Garg, R., & Goldberg, R. B. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108387 · Cited by 25
Phillips, A. E., Wilson, A. S., Greer, P. J., Hinton, A. M., Culp, S., Paragomi, P., Pothoulakis, I., Singh, V. P., Lee, P. J., Lahooti, I., et al. (2023) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00074.2023 · Cited by 20
Jin, J., Hu, X., François, M., Zeng, P., Wang, W., Yu, B., Zhou, Y., & Dong, H. (2023) · European journal of medical research · doi:10.1186/s40001-023-01369-z · Cited by 22
“Obesity is a predominant contributor to MetS, and the presence of the obesity elevates the risk of dyslipidemia by raising the concentration of TG levels and lowering concentration of the HDL-C [31, 32].”
BackgroundUpdate on the management of severe hypertriglyceridemia – focus on free fatty acid forms of omega-3
Catapano, A. L., & Pirillo, A. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s67551 · Cited by 36
“6,18,19 Acquired disorders of metabolism, drugs (estrogens, steroids, and bile acid resins), dietary habits (marked alcohol consumption and high fat ingestion), and medical conditions, including poorly controlled diabetes and nephritic syndrome, 6,18–20 can also contribute.”
BackgroundSchnitzler, J. G., Dallinga‐Thie, G. M., & Kroon, J. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180316121015 · Cited by 27
Hypertriglyceridemia: A review of the evidence
Elkins, J. C., & Friedrich, D. (2018) · The Nurse Practitioner · doi:10.1097/01.npr.0000544997.22887.0b · Cited by 27
Li, X., Guo, X., Ji, H., Niu, J., & Gao, P. (2019) · BioMed Research International · doi:10.1155/2019/2645926 · Cited by 28
Roundtable discussion: Familial chylomicronemia syndrome: Diagnosis and management
Brown, W. V., Goldberg, I., Duell, B., & Gaudet, D. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.02.018 · Cited by 21
Self-citationSyed‐Abdul, M. M., Tian, L., Hegele, R. A., & Lewis, G. F. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00028-2 · Cited by 27
Factors associated with the severity of hypertriglyceridemia induced acute pancreatitis
Vo, T. D., Trinh, N. T. M., & Phát, H. T. (2021) · Medicine · doi:10.1097/md.0000000000025983 · Cited by 21
“Classification of the degree of serum TG according to the 2010 Endocrine Society’s Clinical Practice Guidelines: severe increase (1000–1999mg/dL) and very severe increase in blood TG (≥ 2000mg/dL).”
BackgroundInfluentialYang, Y., Kim, H., Kim, S., Moon, M. K., & Korean Society of Lipid and Atherosclerosis (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0448 · Cited by 26
“Lifestyle modifications such as weight loss, increased physical activity, and medical nutrition therapy, including abstinence from alcohol, are effective in the treatment of hypertriglyceridemia in diabetic patients and may reduce the risk factors for atherosclerotic CVD in some patients [53].”
BackgroundCharacteristics, Physiopathology and Management of Dyslipidemias in Pregnancy: A Narrative Review
Formisano, E., Proietti, E., Perrone, G., Demarco, V., Galoppi, P., Stefanutti, C., & Pisciotta, L. (2024) · Nutrients · doi:10.3390/nu16172927 · Cited by 33
“For this reason, this class of drugs are contraindicated in patients with severe hypertriglyceridemia (>1000 mg/dL) [205,245].”
BackgroundConsensus clinical recommendations for the management of plasma lipid disorders in the Middle East
Sayed, N., Waili, K. A., Alawadi, F., Al-Ghamdi, S. M. G., Almahmeed, W. A., Alnouri, F., Rukhaimi, M. A., Al‐Rasadi, K., Awan, Z. A., Farghaly, M., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.081 · Cited by 23
“fenofibrate, bezafibrate, or ciprofibrate) therapy should be considered an option in patients with elevated levels of plasma TG and low levels of HDL-C despite taking statins [22,28].”
BackgroundInfluentialSemenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00037-7 · Cited by 37
Self-citationYu, S., Yao, D., Liang, X., Jin, K., Fu, Y., Liu, D., Zhang, L., Yang, J., Song, X., Xu, J., et al. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8501 · Cited by 26
Hassan, A., Tajuddin, N. N., & Shaikh, A. (2014) · Cardiology and Therapy · doi:10.1007/s40119-014-0032-9 · Cited by 21
“Two of the three patients with diabetes experienced TG reductions; one patient experienced an increase in TG from 62 to 81 mg/dL, which may not be considered clinically significant, as 81 mg/dL is considered to be within the acceptable range as specified by the guidelines of the NLA [16], AACE [2], and the Endocrine S…”
MethodHoogerland, J. A., Peeks, F., Hijmans, B. S., Wolters, J. C., Kooijman, S., Bos, T., Bleeker, A., van Dijk, T. H., Wolters, H., Gerding, A., et al. (2021) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12380 · Cited by 22
“3 mmol/L are associated with acute pancreatitis.(71) Adenoma progression is significantly increased in GSD Ia subjects with a 5-year mean TG concentration >5.”
BackgroundHe, W., Cai, W., Yang, X., Camilleri, G. M., Zheng, X., Wang, Q., Li, Y., Mukherjee, R., Huang, W., & Sutton, R. (2022) · Pancreatology · doi:10.1016/j.pan.2022.07.013 · Cited by 21
Hypertriglyceridemia-induced acute pancreatitis in children: A mini-review
Grisham, J. M., Tran, A. H., & Ellery, K. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.931336 · Cited by 24
Shafiq, S., Patil, M. N., Gowda, V., & Devarbhavi, H. C. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_206_22 · Cited by 20
Identifying pseudohypertriglyceridemia in clinical practice
Backes, J. M., Dayspring, T. D., Hoefner, D. M., Contois, J. H., McConnell, J. P., & Moriarty, P. M. (2014) · Clinical Lipidology · doi:10.2217/clp.14.52 · Cited by 21
Ashraf, A. P., Hurst, A., & Garg, A. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.03.015 · Cited by 23
“Long-term management of patients with T1HLP involves restricting the dietary fat to,10% to 15% of total energy.(14) Breast milk provides 50% of the energy as fat(15) and can only be given after removal of fat with centrifugation.”
BackgroundHydroxytyrosol nicotinate, a new multifunctional hypolipidemic and hypoglycemic agent
Xie, Y., Chen, Z., Li, N., Lu, W.-F., Xu, Y.-H., Lin, Y., Shao, L.-H., Wang, Q., Guo, L., Yu-qiong, G., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.123 · Cited by 20
Mendelian randomization analysis rules out disylipidaemia as colorectal cancer cause
Ibáñez‐Sanz, G., Díez-Villanueva, A., Riera-Ponsati, M., Fernández‐Villa, T., Fernández‐Navarro, P., Bustamante, M., Llorca, J., Amiano, P., Ascunce, N., Fernández‐Tardón, G., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49880-w · Cited by 21
Wang, X., Meng, H., Ruan, J., Chen, W., & Meng, F. (2021) · Medicine · doi:10.1097/md.0000000000023468 · Cited by 19
“7 mmol/L).([21]) The relative mRNA expression levels of the GOS2 gene in peripheral blood leukocytes of each study subject, expressed as 2, was correlated with blood triglyceride levels.”
BackgroundHirakawa, Y., Lam, T.-H., Welborn, T. A., Kim, H. C., Ho, S. C., Fang, X., Ueshima, H., Suh, I., Giles, G. G., & Woodward, M. (2015) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2015.12.012 · Cited by 21
Pharmacological Effects of Niacin on Acute Hyperlipemia
la Paz, S. M., Bermúdez, B., Naranjo, M. C., López, S., Abia, R., & Muriana, F. J. G. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160411142909 · Cited by 21
Wiesner, P., & Watson, K. E. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.03.004 · Cited by 29
Impact of combined lifestyle factors on metabolic syndrome in Korean men
Lee, J. A., Cha, Y. H., Kim, S. H., & Park, H. S. (2016) · Journal of Public Health · doi:10.1093/pubmed/fdv208 · Cited by 20
Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA
Brinton, E. A., Eckel, R. H., Gaudet, D., Ballantyne, C. M., Baker, B. F., Ginsberg, H. N., & Witztum, J. L. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119114 · Cited by 22
Nie, Z., Xu, J., Cheng, Y., Li, Z., Zhang, R., Zhang, W., & Zhao, L. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01190-y · Cited by 21
“[32].”
Hypertriglyceridemia and acute pancreatitis: clinical and basic research—a narrative review
Gao, L., & Li, W. (2023) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000153 · Cited by 29
“…The definition of HTG is based on blood triglyceride (TG) levels, and it is commonly accepted that a fasting TG level >1.7 mmol/L constitutes HTG. [7] HTG-induced AP (HTG-AP) is of great importance both in clinical practice and research field for the following reasons: 1) the incidence of HTG-AP…”
BackgroundInfluentialLever, M., McEntyre, C. J., George, P. M., Slow, S., Elmslie, J. L., Lunt, H., Chambers, S. T., Parry‐Strong, A., & Krebs, J. D. (2014) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-014-6542-9 · Cited by 17
“Fibrates have been promoted as an adjunct therapy, especially in hypertriglyceridaemia, which is common in type 2 diabetes [12, 13]; however, they can cause apparently unfavourable changes in renal function markers such as plasma creatinine, urea and homocysteine, although these are reversible and there are no changes…”
BackgroundAncestry-specific profiles of genetic determinants of severe hypertriglyceridemia
Gill, P. K., Dron, J. S., Dilliott, A. A., McIntyre, A. D., Cao, H., Wang, J., Movsesyan, I., Malloy, M. J., Pullinger, C. R., Kane, J. P., et al. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.11.007 · Cited by 22
Hypertriglyceridemia-associated acute pancreatitis: Response to continuous insulin infusion
Pulipati, V. P., Amblee, A. P., Yap, S. E. T., Shaka, H., Tahsin, B., & Fogelfeld, L. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260495 · Cited by 18
Koopal, C., Visseren, F. L. J., Westerink, J., van der Graaf, Y., Ginsberg, H. N., & KEECH, A. C. (2018) · Diabetes Care · doi:10.2337/dc17-0968 · Cited by 20
Management of hypertriglyceridaemic pancreatitis in the acute setting and review of literature
Samarasinghe, S., Avari, P., Meeran, K. M., & Cegla, J. (2018) · BMJ Case Reports · doi:10.1136/bcr-2018-227594 · Cited by 20
Feingold, K. R. (2017) · Europe PMC (PubMed Central) · Cited by 18
Affleck, A., Jackson, D., Williams, H. C., Chavez, P., & Albrecht, J. (2022) · British Journal of Dermatology · doi:10.1111/bjd.21840 · Cited by 17
Mahmoud, A., Abdelsayed, K., Mohamed, A. A., Najah, Q., Abdulkader, A., Ali, K., Tabassum, S., Abouzid, M. R., Abdelazeem, B., & Mills, J. D. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-024-02389-2 · Cited by 17
“Therefore, volanesorsen can be recommended in cases of severe HTG or those at risk of acute pancreatitis or high TG-related cardiovascular diseases [42–44].”
Dyslipidemia in childhood and adolescence: from screening to management
Yeung, E., Daniels, S. R., & Patel, S. S. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000607 · Cited by 20
“Expert recommendations suggest genetic testing for patients with triglycerides more than 1000 mg/dl, however these disorders are very rare [37].”
BackgroundNewman, J. W. I., Krishnan, S., Borkowski, K., Adams, S. H., Stephensen, C. B., & Keim, N. L. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.877696 · Cited by 22
Acute Pancreatitis during and after Pregnancy: A Review
Maringhini, A., Rossi, M., Patti, R., Maringhini, M., & Vassallo, V. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072028 · Cited by 20
“So, early diagnosis and correct therapy are the main goals in managing AP in pregnancy [31].”
BackgroundGenomic and transcriptomic predictors of triglyceride response to regular exercise
Sarzynski, M. A., Davidsen, P. K., Sung, Y. J., Hesselink, M. K. C., Schrauwen, P., Rice, T., Rao, D. C., Falciani, F., & Bouchard, C. (2015) · British Journal of Sports Medicine · doi:10.1136/bjsports-2015-095179 · Cited by 21
Diakoumakou, O., Hatzigeorgiou, G., Gontoras, N., Boutsikou, M., Kolovou, V., Mavrogeni, S. I., Giannakopoulou, V., & Kolovou, G. D. (2014) · Cholesterol · doi:10.1155/2014/109263 · Cited by 20
“6mmol/L) one should be focused on the risk of premature CHD [13].”
BackgroundInfluentialLi, X., Yang, Q., Shi, X., Chen, W., Pu, N., Li, W., & Li, J. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0789-2 · Cited by 17
“At his last update, the patient had a remarkable and consistent reduction in TG and even could be defined as having moderate hypertriglyceridemia [18].”
Financial Conflicts of Interest Among Authors of Endocrine Society Clinical Practice Guidelines*
Irwig, M. S., Kyinn, M., & Shefa, M. C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00526 · Cited by 20
Miyamoto, L., Egawa, T., Oshima, R., Kurogi, E., Tomida, Y., Tsuchiya, K., & Hayashi, T. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00162.2013 · Cited by 18
Hypertriglyceridemic pancreatitis
de Pretis, N., Marchi, G. D., & Frulloni, L. (2020) · Minerva Gastroenterologica e Dietologica · doi:10.23736/s1121-421x.19.02641-2 · Cited by 18
Lin, N., Cui, W., Li, X., Chang, J., & Xue, X. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02050-9 · Cited by 18
“Hypertriglyceridemia was defined according to the Clinical Practice Guidelines on Hypertriglyceridemia from the Endocrine Society [33].”
MethodAssociation between triglyceride and depression: A systematic review and meta-analysis
Xu, D.-R., Gao, X., Zhao, L., Liu, S., Tang, G., Zhou, C., & Chen, Y. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311625 · Cited by 23
FTY720 Attenuates Acute Pancreatitis in Hypertriglyceridemic Apolipoprotein CIII Transgenic Mice
Liu, J., Xu, P., Zhang, L., Kayoumu, A., Wang, Y., Wang, M., Gao, M., Zhang, X., Wang, Y., & Liu, C. (2015) · Shock · doi:10.1097/shk.0000000000000400 · Cited by 16
“This is in sharp contrast to clinical situation, in which only severe HTG with plasma TG exceeding 1,000 mg/dL is considered as a risk factor for attack of HTGP (19).”
ResultChang, C., Lin, X.-R., Lin, Y.-L., Fang, W.-H., Lin, S., Chang, S., & Kao, J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192740 · Cited by 17
Nomogram Including Neutrophil-to-Lymphocyte Ratio for the Prediction of Stroke-Associated Infections
Lan, Y., Sun, W., Chen, Y., Miao, J., Guo, L., Qiu, X., Song, X., Zhao, X., Zhu, Z., Fan, Y., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.574280 · Cited by 18
Metadata
- Authors
- Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H.
- Affiliations
- University of California, Davis (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- Columbia University (US)
- Harvard University (US)
- Mayo Clinic (US)
- Radboud University Medical Center (NL)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-09-01
- Volume
- 97
- Issue
- 9
- Pages
- 2969-2989
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3431581
- OpenAlex
- W2111416524
- Cited by
- 887
- References
- 206
- Citations by year
- 2026: 55 · 2025: 54 · 2024: 74 · 2023: 62 · 2022: 72 · 2021: 74 · 2020: 83 · 2019: 61 · 2018: 89 · 2017: 50 · 2016: 62 · 2015: 57 · 2014: 48 · 2013: 41
- FWCI
- 47.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- American Heart Association
- European Society of Endocrinology
- National Heart, Lung, and Blood Institute (R01HL045095)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- hypertriglyceridemia, triglyceride levels, fasting triglycerides, cardiovascular risk, pancreatitis, secondary hyperlipidemia, familial hypertriglyceridemia, dyslipidemia, non-HDL cholesterol, lifestyle therapy, fibrate therapy
- MeSH terms
- Exercise Therapy, Humans, Terminology as Topic, Triglycerides, Hypertriglyceridemia, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.